Hold Dr Reddy’s Laboratories; target of Rs 2610: ICICI Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

ICICI Direct's research report on Dr Reddy’s Laboratories

US business grew 15% to Rs 6360 crore over FY12-17 mainly driven by new launches. US remains a key driver for the company, contributing 45% to total revenues. Current US pending pipeline comprises 101 pending approvals (62 Para IV filings and 21 FTFs) including two NDAs. The company has developed a knack for exclusivity/FTF launches on a fairly continuous basis in US.

Outlook

Apart from US, Global Generics (ex US, Europe) growth is expected to recover on the back of stabilise currency, geographical expansion, robust biosimilar portfolio and ramp up in institutional business. We have ascribed a target price of Rs 2610 based on 19x FY19E EPS of Rs 137.

For all recommendations, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More